Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500970PMID: 30000029
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 24584-09-6
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of dexrazoxane during breastfeeding. The manufacturer recommends that women not breastfeed during treatment and for 2 weeks following the final dose of dexrazoxane. However, because dexrazoxane is used with doxorubicin, the abstinence period might be longer, depending on the doxorubicin dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Dexrazoxane
CAS Registry Number
24584-09-6
Drug Class
Breast Feeding
Antineoplastic Agents
Cardioprotectants
Cardiotonic Agents
Enzyme Inhibitors
Topoisomerase II Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Temozolamide.[Drugs and Lactation Database (...]Review Temozolamide.. Drugs and Lactation Database (LactMed®). 2006
- The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites.[Drug Metab Dispos. 2008]The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites.Schroeder PE, Patel D, Hasinoff BB. Drug Metab Dispos. 2008 Sep; 36(9):1780-5. Epub 2008 May 30.
- Review Fenofibrate.[Drugs and Lactation Database (...]Review Fenofibrate.. Drugs and Lactation Database (LactMed®). 2006
- Review Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity.[Cancer Treat Rev. 1991]Review Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity.Curran CF, Narang PK, Reynolds RD. Cancer Treat Rev. 1991 Dec; 18(4):241-52.
- Review Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.[Support Care Cancer. 1996]Review Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.Hellmann K. Support Care Cancer. 1996 Jul; 4(4):305-7.
- Dexrazoxane - Drugs and Lactation Database (LactMed®)Dexrazoxane - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...